Inclusion Criteria:

• Signed informed consent form.
• Male or female ≥18 years of age at Screening Visit 1.
• Documented physician diagnosis of asthma for ≥12 months prior to Screening Visit 1.
• Participants requiring at a minimum low dose maintenance inhaled corticosteroids (ICS; ≥100 μg/day fluticasone propionate daily or clinically comparable, per 2021 Global Initiative for Asthma [GINA] guidelines). The ICS may be contained within an ICS/LABA combination product.
• Use of daily ICS must be for at least 12 weeks prior to Screening Visit 1 and the doses of all controller medications must be stable for at least 4 weeks prior to Screening Visit 1.

Exclusion Criteria:

• Age <18 years old.
• History of upper/lower respiratory tract infection or asthma exacerbation at any time from 4 weeks prior to Screening Visit 1.
• Any other significant medical issue as determined by the principal investigator.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 07/15/2024. Questions regarding updates should be directed to the study team contact.